Capstone Therapeutics Corp (CAPS) 0.1700 $CAPS Capstone

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Capstone Therapeutics Corp (CAPS) 0.1700 $CAPS

Capstone Therapeutics, Inc. - "Following the Data"
ACCESSWIRE - Mon Apr 27, 7:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2015 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and CEO, Jock Holliman, and President of LipimetiX Development, LLC, Dennis I. Goldberg, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Capstone Therapeutics Announces Operating Update Conference Call
GlobeNewswire - Fri Mar 20, 10:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company", will hold a conference call and webcast on Thursday, March 26, 2015 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning March 26, 2015 at 7:30 pm EDT until midnight March 29, 2015, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 9888102.

Capstone Could Succeed with AEM-28 Where Aegerion and Sanofi Failed
ACCESSWIRE - Wed Jan 28, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Cholesterol-reducing statins like Pfizer's (NYSEFE) Lipitor may be the best selling prescription drug class in history, but for one kind of cholesterol disease, statins are just a pharmacological drop in the bucket.
ISIS: 64.33 (+1.78), PFE: 33.98 (-0.01), AEGR: 19.47 (+0.19), SNY: 50.40 (-0.12)

Capstone Therapeutics, Inc. - "Importance of VLDL and Triglycerides in Cardiovascular Disease"
ACCESSWIRE - Tue Dec 16, 11:49AM CST
New York, NY / ACCESSWIRE / December 16, 2014 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
GlobeNewswire - Tue Dec 16, 7:37AM CST
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV", announced today the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction. The top-line data from the Phase 1a (reported on September 2, 2014) and Phase 1b/2a blended protocol has been analyzed. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed a generally acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints, which included:

Capstone Therapeutics Corps' CEO Discusses Q3 2014 Earnings Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:05PM CST


Capstone Therapeutics Will Provide an Operating Update and Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 8:00AM CST
Capstone Therapeutics (OTCQB:CAPS); (the "Company", today will hold a conference call and webcast to provide an operating update and announced financial results for the third quarter 2014.

Capstone reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:21AM CST


Capstone Therapeutics Announces Third Quarter 2014 Financial Results and Operating Update Conference Call
GlobeNewswire - Thu Nov 06, 9:00AM CST
Capstone Therapeutics (OTCQB:CAPS); (the "Company", will hold a conference call and webcast on Thursday, November 13, 2014 at 4:30 pm EST. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning November 13, 2014 at 7:30 pm EST until midnight November 16, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 22735607.

Capstone Therapeutics, Inc. - "AEM-28 Drug Class May Serve Larger Cardiovascular Markets"
ACCESSWIRE - Tue Oct 07, 7:51AM CDT
New York, NY / October 7, 2014 / Capstone Therapeutics (OTCQB: CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Capstone Therapeutics Corp. Announces Digital Corporate Communication Channels
GlobeNewswire - Fri Sep 05, 12:09PM CDT
Capstone Therapeutics Corp. (OTCQB:CAPS) (the "Company" or "Capstone Therapeutics", a clinical stage biotechnology company developing a family of new peptide drugs, announced today its suite of online corporate communication channels to maintain on-going direct communication with stakeholders. The Company has launched official portals on social media channels including Facebook, Twitter, Google+ and The Chairman's Blog.

Capstone Therapeutics, Inc. - "A New Class of Cardiovascular Drug"
ACCESSWIRE - Fri Sep 05, 7:48AM CDT
New York, NY / September 5, 2014 / Capstone Therapeutics (OTCQB: CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, Jock Holliman. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
GlobeNewswire - Tue Sep 02, 8:57AM CDT
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV", announced today the completion of dosing and patient follow-up for its investigational AEM-28 (Apo E mimetic peptide) Phase 1a human clinical trial in cholesterol and lipid reduction. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed an acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, biomarker efficacy measurements analyzing pharmacodynamics yielded trends favoring AEM-28 versus placebo in multiple cholesterol and lipid endpoints.

Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 8:05AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company", today will hold a conference call and webcast to provide an operating update and announced financial results for the second quarter 2014.

Capstone Therapeutics Announces Second Quarter 2014 Financial Results and Operating Update Conference Call
GlobeNewswire - Wed Aug 06, 9:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company", will hold a conference call and webcast on Thursday, August 14, 2014 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning August 14, 2014 at 7:30 pm EDT until midnight August 17, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 81563431.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KickHouse Partners with Sam Alvey for Glove Line Launch

Updated Category News Views 33

KickHouse Pounces with New Fighter Partnership Looks like KickHouse isn't playing games, folks. They've teamed up with fighter Sam Alvey to launch a new boxing glove line. You got your Warbird, your Desert Ghost, and your Night Ops gloves—names straight out of a war zone. These 16-ounce hammers are out now, and they kickstart a broader gear lineup custom-built for Alvey...

Continue Reading
Reddit's Stock Plunge Sparks Legal Scrutiny

Updated Category News Views 116

Reddit's Big Gamble: A Risky Shift Investors, grab your coffee, because Reddit (NYSE: RDDT) just gave us a real eyebrow-raiser, and no one's got a clue how deep this rabbit hole goes. They pulled the curtains back and went for a logged-in-only format, and the stock took a nosedive—a good 28% drop, just like that. If you've got a vested interest here, this is your cue to...

Continue Reading
BAILOR Welcomes Co-Founder Bob Bailor to Coach Academy

Updated Category News Views 75

A New Chapter for a Seasoned Entrepreneur There's a certain irony in a seasoned business vet stepping into a new role at his own daughter's company, and that's exactly what's unfolding with the Bailors. Huntsville's own BAILOR isn't just another growth strategy company; it's the embodiment of a father-daughter dream team. After years as the ordinary head honcho, Bob...

Continue Reading
SMTC: Thriving with Innovation in EMS Landscape

Updated Category News Views 42

Trailblazing in the Evolving EMS Arena SMTC's latest accolade from Frost & Sullivan isn't just another feather in their cap. It's a testament to how this mid-tier electronics manufacturing services (EMS) player stands head and shoulders above the rest. While other companies are fumbling with supply chain headaches and shifting market demands, these folks are buckling down...

Continue Reading
Navigating Holiday Eating with GLP-1 Support

Updated Category News Views 39

GLP-1 Programs: A New Holiday Challenge As if the holidays weren't already a puzzle with family dinners and over-the-top office parties, folks on a GLP-1 program have another set of questions, like navigating a buffet without guilt. Ain’t no sugarcoating it—December throws every routine straight out the window. It's not just about what pie to eat, but how to keep your...

Continue Reading
FirstEnergy Pumps $115K into PA Housing Stability

Updated Category News Views 20

Bankrolling Hope: FirstEnergy's $115K Commitment On the surface, corporate philanthropy sounds like yet another PR stunt, but sometimes these dollars pour a lifeline for those in dire need. Today, we look at FirstEnergy Foundation throwing a weighty $115,000 towards ensuring Pennsylvanians have stable roofs over their heads. This isn't your garden-variety donation—a lot...

Continue Reading
ServiceTitan Faces Investor Fury: Revenue Surprise

Updated Category News Views 93

A Crippling Blow for ServiceTitan Investors When you're in the investing game long enough, you start to recognize the scent of trouble before it even hits the fan. In the case of ServiceTitan, Inc. (NASDAQ: TTAN), the smell came wafting in strong when the stock took a nosedive on September 9, 2026. Investors were left clutching their portfolios with bewilderment as shares...

Continue Reading
Scientology Teams with Red Cross in Amazon Aid Effort

Updated Category News Views 22

Intersecting Paths in the Amazon Deep in the heart of the Amazon, where Colombia meets Brazil and Peru, something unique is happening. The Scientology Volunteer Ministers, amid their Amazon Extreme Pioneer Tour, have joined forces with the Colombian Red Cross and the Correcaminos Foundation to host a community outreach event near Leticia. This isn’t some fly-by-night...

Continue Reading
Conquering Dental Anxiety: Tips for a Calm Visit

Updated Category News Views 7

Breaking the Fear of the Dentist's Chair There's no sugar-coating it—hitting the dental chair can feel like gearing up for a bout in the boxing ring, especially if anxiety's already taken root. But listen, it doesn't have to be that way, and that's where HelloNation's recent feature steps in. Dr. Adriane Lippian and Dr. Jim Lippian, dentists hailing from Texarkana,...

Continue Reading
TCL Powers Senegal's Youth Olympics with Solar Display

Updated Category News Views 35

Innovative Display Tech Lands in Senegal Cutting through the noise of corporate clutter, TCL just made a move in Senegal that's got layers deeper than a PR stunt. They’ve handed over an ultra-low-power display system to the Université Amadou Mahtar Mbow (UAM) in Dakar, which is also moonlighting as the Youth Olympic Village for the 2026 Games. This isn't just any...

Continue Reading

Top 5 Most Recently Viewed Articles

Commerce Split Corp. Keeps Preferred Share Rates Steady

Updated Category News Views 105

Commerce Split Corp. Preferred Shares Remain Steady Commerce Split Corp., a lively participant in the investment world, has recently confirmed that the annual rates for their Preferred Shares will remain unchanged as they transition into a new five-year term beginning December 1, 2024. Investors can look forward to the Class I Preferred Shares maintaining an appealing...

Continue Reading
Understanding the Recent Short Interest on MercadoLibre Stocks

Updated Category News Views 141

Examining Recent Trends in MercadoLibre's Short Interest MercadoLibre (MELI) has seen a notable increase in its short percent of float, which has escalated by 8.87% since the last reporting period. Currently, this reflects that the company has 683 thousand shares sold short, representing 1.35% of all shares available for trading. Traders may find it significant that,...

Continue Reading
UFCU Appoints Sumeet Grover as Chief Growth and Digital Officer

Updated Category News Views 387

UFCU Welcomes Sumeet Grover to Leadership Team University Federal Credit Union (UFCU), a prominent financial institution known for its commitment to growth and service, recently announced the appointment of Sumeet Grover as its Executive Vice President and Chief Strategic Growth and Digital Officer. Grover brings a wealth of experience and forward-thinking strategies...

Continue Reading
Organon Takes Major Step Acquiring Dermavant for $1.2B

Updated Category News Views 176

Organon Expands Portfolio by Acquiring Dermavant Organon & Co has agreed to acquire Dermavant Sciences Ltd from Roivant Sciences Ltd. Dermavant is known for its work in developing and commercializing treatments for dermatological conditions. This acquisition demonstrates Organon’s strategic initiative to strengthen its presence in the dermatology market, particularly by...

Continue Reading
Investing in Dividends: A Journey to Earning Passive Income

Updated Category News Views 86

The Appeal of Dividend Stocks As investors increasingly seek to create steady income streams, dividend stocks have become a favored option. The ongoing uncertainty around interest rate changes has sparked a greater interest in investments that can ensure a consistent flow of income. Historically, dividend stocks have been crucial in shielding investors from inflation. A...

Continue Reading